Jul 2020
ANTG’s Eve Cannabis product reveals its potential to kill or inhibit cancer cells without impacting normal cells...
LEARN MORE >
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
In an exclusive interview with 60 Minutes, Olivia Newton-John, Australian actress who is recovering from her third breast cancer continues to credit medical cannabis with helping her manage not only the pain, but also sleep and anxiety.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
What’s most important in business – purpose or profit? At ANTG we get to achieve both.
We’re pleased to announce we have successfully passed the TGO93 and TGO100 mandatory tests for our first commercial export crop.
ANTG’s James Gaskell joins 2SER Breakfast on 107.3 to discuss his thoughts on ACT’s recent legalisation of cannabis, the conflict of state vs federal laws, and the medicinal cannabis industry in Australia and abroad.
In the first 12 months we expect to see two tonnes plus in export. Exportation will begin to Germany, where we have signed a 10-year supply contract with Cannamedical Pharma.
A report into the Narcotic Drugs Act (ND Act) has recommended several changes to medical cannabis regulation in Australia.
The Morrison government is prioritising the medicinal cannabis industry and from September the Office of Drug Control will fast track new licences for all projects that have a big impact on exports, jobs or industry growth.
The latest national survey from Chronic Pain Australia found that more than a third of respondents said, after discussing medicinal cannabis as a pain treatment with their GP that they faced difficulty when it came around to the approval process.
As a response to more than 10,000 prescriptions for medicinal cannabis that have been written in Australia so far, The Morrison government is planning on prioritising new licences for projects granted “major project status” by the industry department.
LUNG CANCER PATIENT SAYS HE TURNED TO CANNABIS OIL TO […]
CANBERRA PATIENTS STILL FACING HURDLES WHEN ACCESSING MEDICINAL CANNABIS It […]
NEW DOCUMENTARY SHEDS NEW LIGHT ON MEDICINAL CANNABIS IN AUSTRALIA […]
‘High as Mike’, a new documentary which tells the story of Tamworth-based brain cancer patient Mike Gallanger sheds new light on regulations around medicinal cannabis and explains the ways it works to help Australians understand the industry and issues surrounding the drug.
‘High as Mike’, a new documentary which tells the story of Tamworth-based brain cancer patient Mike Gallanger sheds new light on regulations around medicinal cannabis and explains the ways it works to help Australians understand the industry and issues surrounding the drug.
Chris Wright, Brisbane local who was diagnosed with Tourette’s syndrome at the age of 12 is one of the first patients recruited for the trial run by Brisbane’s Wesley Medical Research. Read about the trial here.
Thanks to new streamlined processes, Queensland specialist doctors soon will be able to prescribe medicinal cannabis directly to their patients, meaning the medicine will be treated just like any other prescription drug in Queensland.
Growing cannabis for medicinal use has a huge potential in Australia. However, due to the nature of the plant, there is still stigma associated with cultivating medicinal cannabis.
ANTG becomes first Australian member of The Global Cannabis Partnership (GCP), not-for-profit collaboration of leaders in the government-sanctioned cannabis industry. The partnership offers a great opportunity for the company to take part in shaping the future of medicinal cannabis industry.
Our CEO and founder, Matt Cantelo has met with the business editor at The Sydney Morning Herald to discuss the future of medicinal cannabis in Australia, ANTG’s export plans and company’s current investments into research.
As access to medicinal cannabis in Australia remains limited, more ageing Australians looking for pain relief are turning to illegal sources for cannabis medication.
A story of six year old Cooper who has been diagnosed with Epilepsy two years ago. After trying a range of traditional medications over the years with very little success, Cooper’s parents decided to start on medicinal product to help him with seizures that have eventually stopped.
To help Australian patients easily access the best quality medicinal cannabis, Greg Hunt, the health minister has launched Medicinal Cannabis Industry Australia. The role of this newly created industry body will be to ensure that medicinal cannabis products achieve the highest standards to meet patients’ individual needs.
Perth’s first medicinal cannabis clinic has been opened in Subiaco. This clinic is the fourth location in Australia and has been set up to streamline access to medicinal cannabis and help to speed up the application process.
A new law has been passed by the New Zealand Government which will allow terminally ill patients to access cannabis for medicinal use. The law will also allow medicinal cannabis to be manufactured in the country and exported overseas. New regulations are expected to be in place within a year.
Our CEO and founder, Matt Cantelo has recently met with the editor of the local newspaper, The Northern Daily Leader to discuss ANTG’s partnership with Cannamedical Pharma, German pharmaceutical company and its plans for growth, including the opening of their new facility in Armidale.
Matt Cantelo recently sat down with leading business publication, My Business to discuss the future of the Australian medicinal cannabis industry, ANTG’s plans for growth, the role of the industry to facilitate greater research and ANTG’s exciting partnership to export Australian grown cannabis to the German market.
A new world-first trial will examine whether oral medicinal cannabis can affect tumour growth in patients with glioma, a common type of brain cancer.
The process of acquiring medicinal cannabis may soon become a lot easier for patients living in Queensland. Health Minister Steven Miles introduced a bill to repeal the Public Health (Medicinal Cannabis) Act 2016.
Tasmania remains the only state in Australia unable to use an online application system that helps streamline access to medicinal cannabis. Unnecessary hurdles are also said to be experienced with people needing to see their GP first to obtain a referral to a relevant specialist. Experts claim that this process creates an unnecessary burden on health system and extends the waiting time for patients.
A new survey has found that even though the cost of medicinal cannabis has significantly decreased over the past year the pricing is still too high for many Australians.
Olivia Newton-John, who is battling cancer for the third time, has revealed that following radiation therapy she been using cannabis oil to treat her cancer symptoms, such as pain.
Despite medicinal cannabis being decriminalized across the country, due to uneven legislation across states governing the prescription and use of medical cannabis, it remains difficult to source.
Sydney businessman Barry Lambert, who was found guilty of possession and cultivation of cannabis in 2017, claims that hemp extract was the only thing that helped to stop his granddaughter’s seizures.
Latest data shows that since it became easier for doctors to prescribe medicinal cannabis in New South Wales, 322 applications have been approved.
A study conducted by researchers from The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney found that almost two thirds of 640 Australian GPs surveyed have had patients ask about the drug.
A study conducted by researchers from The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney found that almost two thirds of 640 Australian GPs surveyed have had patients ask about the drug.
TEN NEW MEDICINAL CANNABIS CLINICS TO OPEN IN MELBOURNE THIS […]
AUSTRALIAN PATIENTS TRAVELLING OVERSEAS FOR MEDICINAL CANNABIS Eighteen months on from […]
MEDICINAL CANNABIS EXPORTS APPROVED BY FEDERAL GOVERNMENT Following an extensive […]
MEDICINAL CANNABIS IN AUSTRALIA: HOW LEGAL IS IT? Following the […]
FIRST AUSTRALIAN TRIAL TO EXPLORE EFFECTS OF MEDICINAL CANNABIS ON […]
VICTORIAN CHILDREN TO ACCESS MEDICAL CANNABIS IN EPILEPSY TRIAL Twenty-nine […]
UNIFIED ACCESS SYSTEM FOR MEDICAL CANNABIS NEEDED Blue Mountains GP […]
The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development new clinical guidance documents for medicinal cannabis products.
MEDICINAL CANNABIS ACCESS REGULATIONS ‘UNWORKABLE’ An Adelaide GP has criticised […]
ADMINISTRATIVE OBSTACLES SLOW MEDICINAL CANNABIS UPTAKE IN NSW In the […]
LUCY HASLAM STRIVES TO IMPROVE MEDICINAL CANNABIS ACCESS FOR PATIENTS […]
RACGP PRESIDENT CRITICISES MEDICAL CANNABIS REGULATION The Royal College of […]
FIRST TASMANIANS APPROVED UNDER NEW SCHEME TO USE MEDICINAL CANNABIS […]
Liberal Democrats Senator David Leyonhjelm has called on the federal government to ‘quit dithering’ and cut the red tape preventing thousands of Australians suffering chronic pain from accessing medicinal cannabis.
NSW GOVERNMENT ACCUSED OF DELAYING ACCESS TO MEDICAL CANNABIS Shadow […]
QUEENSLAND LEADS WITH WORLD-FIRST MEDICINAL CANNABIS TRIAL A Queensland trial […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla at massa in neque egestas pellentesque. Donec nec urna sodales, bibendum justo vel, porta libero. Praesent id libero eros. Nullam elementum, ipsum ac hendrerit suscipit, risus mi feugiat erat, quis faucibus eros velit et turpis.
The NSW Government has launched the country’s first cannabis medicines hotline. The hotline – part of a $21 million investment in cannabis medicines research – will simplify and speed up access for doctors whose patients may benefit from this type of treatment. The service will provide guidance for the use of cannabis medicines, including advice on clinical management, available medicines, and dosage information.
ANTG’s Eve Cannabis product reveals its potential to kill or inhibit cancer cells without impacting normal cells…
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
The results from an Australian national online survey was released last month into the use of cannabis as a self-management strategy for endometriosis. The survey aimed to determine the occurrence, tolerance and effectiveness of cannabis use for Australian women with endometriosis.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
Based on data collected as a part of the treatment program of 188 patients, medicinal cannabis appears to be a well-tolerated, safe and effective option to help with symptoms associated with autism spectrum disorders.
The latest national survey from Chronic Pain Australia found that more than a third of respondents said, after discussing medicinal cannabis as a pain treatment with their GP that they faced difficulty when it came around to the approval process.
The aim of this retrospective chart review was to determine whether CBD can help improve sleep and/or anxiety.
The aim of this interview-based study on 34 registered pharmacists in Australia was to explore their views on access to medicinal cannabis and barriers from a supplier’s perspective.
‘High as Mike’, a new documentary which tells the story of Tamworth-based brain cancer patient Mike Gallanger sheds new light on regulations around medicinal cannabis and explains the ways it works to help Australians understand the industry and issues surrounding the drug.
The aim of this randomised, survey-based study on patients aged 75+ was to assess the effects and safety of medicinal cannabis in elderly patients. Read the results.
Here we aim to improve education beyond medicinal cannabis in treating chronic illness and disease, and acknowledge one of the lesser known uses of medicinal cannabis – anxiety.
Chris Wright, Brisbane local who was diagnosed with Tourette’s syndrome at the age of 12 is one of the first patients recruited for the trial run by Brisbane’s Wesley Medical Research. Read about the trial here.
The aim of this survey-based study was to assess the effects of medicinal cannabis on severe nausea and vomiting during pregnancy. The results based on interviews with 84 female patients show that medicinal cannabis can help treat the condition however the study also supports the need for further investigations.
The results of the retrospective survey show that medicinal cannabis can improve symptoms of Parkinson disease in the initial stages.
The aim of the survey completed by 640 Australian general practitioners (GP) was to examine the knowledge and attitudes of GP towards medicinal cannabis. The results show that the majority of surveyed practitioners are supportive or neutral when it comes to medicinal cannabis use.
A story of six year old Cooper who has been diagnosed with Epilepsy two years ago. After trying a range of traditional medications over the years with very little success, Cooper’s parents decided to start on medicinal product to help him with seizures that have eventually stopped.
The results show that medicinal cannabis can significantly affect levels of the appetite hormones and be considered as a supporting medicine when treating eating disorders and obesity.
The results show that medicinal cannabis has a reasonable safety profile and can help with pain management, quality of life and cognitive function.
This review of 49 studies assesses the use of medicinal cannabis for anxiety-related disorders. The available evidences demonstrates there is a potential benefit of cannabinoids in reducing anxiety behaviors relevant to disorders such as PTSD, GAD, PD, OCD, and SAD, with no anxiogenic effects. The authors emphasise the potential value and need for further study of CBD in the treatment of anxiety disorders.
A new world-first trial will examine whether oral medicinal cannabis can affect tumour growth in patients with glioma, a common type of brain cancer.
The review of 24 reports evaluates the use of medicinal cannabis for psychiatric, movement and neurodegenerative disorders. The available evidences suggest there is a potential benefit of cannabinoids for those diseases however further research is required to confirm its efficacy.
Despite medicinal cannabis being decriminalized across the country, due to uneven legislation across states governing the prescription and use of medical cannabis, it remains difficult to source.
A double-blind, placebo-controlled trial on 120 children and young adults with the Dravet syndrome and drug-resistant seizures shows that cannabidiol reduces the frequency of convulsive seizures.
Systematic review of 13 studies shows that cannabis-based medicinal extracts may provide effective pain relief to patients suffering with chronic nonmalignant neuropathic pain, especially with conditions that are resistant to other treatments.
A study conducted by researchers from The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney found that almost two thirds of 640 Australian GPs surveyed have had patients ask about the drug.
The study collected data from 65 families to explore their experiences with medicinal cannabis to help treat their children’s epilepsy.
The review of preclinical studies outlining the role of cannabinoids in the modulation of headache pathogenesis.
MEDICINAL CANNABIS EXPORTS APPROVED BY FEDERAL GOVERNMENT Following an extensive […]
Study assessing the efficacy and safety of cannabidiol as an add-on anticonvulsant
The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development new clinical guidance documents for medicinal cannabis products.
A systematic review and meta-analysis on the efficacy, tolerability, and safety of cannabinoids in palliative medicine.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla at massa in neque egestas pellentesque. Donec nec urna sodales, bibendum justo vel, porta libero. Praesent id libero eros. Nullam elementum, ipsum ac hendrerit suscipit, risus mi feugiat erat, quis faucibus eros velit et turpis.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.
LEARN ABOUT ANTG HERE >
